Novartis AG (NVS) News
Latest headlines that mention NVS, newest first · each headline opens the original publisher
- Last price
- $143.11
- Day change
- -0.12%
- Next earnings
- 2026-10-27 BMO
NVS headlines
last 30 daysNovartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.
Find insight on Novartis, UCB and more in the latest Market Talks covering Health Care.
Find insight on UCB, Novartis and more in the latest Market Talks covering the health care sector.
Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease. The post Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares appeared first on Investor's Business Daily .
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.
The drugmaker saw its second late-stage trial miss in days, and Wall Street is now questioning its growth targets.
Novartis AG shareholder Artisan Partners said the Swiss drugmaker needs to shake up its board and improve dealmaking after its shares plunged following three major clinical trial setbacks, Reuters reported.
Also mentioned with NVS
30dHeadlines that tag both tickers
NVS news alerts
Get an alert by email or push when a new headline mentions NVS.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.